CD137 Protein (Fc Tag)

Catalog No. ABIN7121389

Recombinant CD137 protein expressed in HEK-293 Cells.

Quick Overview for CD137 Protein (Fc Tag) (ABIN7121389)

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Protein Type: Recombinant

Origin: Dog

Source: HEK-293 Cells

Purity: >95 % as determined by SDS-PAGE.

Grade: MALS verified

Product Details

Purification tag / Conjugate: This CD137 protein is labelled with Fc Tag.

Purpose: Canine 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)

Sequence: Ile 24 - Ser 185

Characteristics: Canine 4-1BB Protein, Fc Tag (41B-C5253) is expressed from human 293 cells (HEK293). It contains AA Ile 24 - Ser 185 (Accession # XP_850336.1).

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Application Notes: This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 43.4 kDa. The protein migrates as 55-65 kDa under reducing (R) condition due to glycosylation.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH 7.5

Storage: -20 °C

Storage Comment: -20°C

Target Details

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Alternative Name: 4-1BB / TNFRSF9

Background: Synonyms: TNFRSF9,4-1BB,CD137,CDw137,ILA,
Description: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Molecular Weight: 43.4 kDa

NCBI Accession: XP_850336

Pathways: Cancer Immune Checkpoints